Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights
Globe Newswire•12/11/2026•16:01 ET
0
Key Highlights
- ➤$402.5 million cash, expected to fund planned operations into 2029
- ➤$23.9 million third-quarter net loss, versus $18.1 million loss in 2025
- ➤Ipsoprubart sHLH registrational enrollment completion expected in second half of 2027
- ➤Ipsoprubart T/NK malignancy trial initial data expected in second half of 2027
- ➤ELA822 healthy-volunteer data expected first half of 2027; patient trial planned mid-2027
Expert Statements
Kathy Dong, President and Chief Executive Officer of Electra Therapeutics
“Our recent IPO positions Electra to build on its first-mover advantage in SIRP-targeted precision immune cell depletion”
Kathy Dong, President and Chief Executive Officer of Electra Therapeutics
“Our deep expertise in SIRP biology and proprietary library of SIRP-targeting antibodies enable us to selectively address distinct pathogenic immune cell populations, creating therapeutic optionality across immune-mediated diseases and cancer.”
Kathy Dong, President and Chief Executive Officer of Electra Therapeutics
“Building on compelling clinical data in sHLH, we are advancing ipsoprubart through a global registrational program and evaluating its potential in T/NK cell malignancies.”
Kathy Dong, President and Chief Executive Officer of Electra Therapeutics
“With ELA822 now in Phase 1, we are advancing multiple programs with the potential to benefit patients and create value for our stakeholders.”
Kathy Dong, President and Chief Executive Officer of Electra Therapeutics
“We anticipate several important milestones in 2027, including ELA822 healthy volunteer data expected in the first half of the year, followed by ipsoprubart data in T/NK cell malignancies and completion of enrollment in the sHLH registrational program in the second half.”
Ipsoprubart Advancing in Global Registrational Program as Potential First Treatment for sHLH Broadly; Enrollment Completion Expected in Second Half of 2027
Ipsoprubart Therapeutic Expansion Underway in Phase 1 Trial for T/NK Cell Malignancies, with Initial Data Expected in the Second Half of 2027
Get started
Create a free account to read the full story.